Literature DB >> 23686495

GB virus C particles inhibit T cell activation via envelope E2 protein-mediated inhibition of TCR signaling.

Nirjal Bhattarai1, James H McLinden, Jinhua Xiang, Alan L Landay, Ernest T Chivero, Jack T Stapleton.   

Abstract

Viruses enter into complex interactions within human hosts, leading to facilitation or suppression of each other's replication. Upon coinfection, GB virus C (GBV-C) suppresses HIV-1 replication in vivo and in vitro, and GBV-C coinfection is associated with prolonged survival in HIV-infected people. GBV-C is a lymphotropic virus capable of persistent infection. GBV-C infection is associated with reduced T cell activation in HIV-infected humans, and immune activation is a critical component of HIV disease pathogenesis. We demonstrate that serum GBV-C particles inhibited activation of primary human T cells. T cell activation inhibition was mediated by the envelope glycoprotein E2, because expression of E2 inhibited TCR-mediated activation of Lck. The region on the E2 protein was characterized and revealed a highly conserved peptide motif sufficient to inhibit TCR-mediated signaling. The E2 region contained a predicted Lck substrate site, and substitution of an alanine or histidine for the tyrosine reversed TCR-signaling inhibition. GBV-C E2 protein and a synthetic peptide representing the inhibitory amino acid sequence were phosphorylated by Lck in vitro. The synthetic peptide also inhibited TCR-mediated activation of primary human CD4(+) and CD8(+) T cells. Extracellular microvesicles from GBV-C E2-expressing cells contained E2 protein and inhibited TCR signaling in bystander T cells not expressing E2. Thus, GBV-C reduced global T cell activation via competition between its envelope protein E2 and Lck following TCR engagement. This novel inhibitory mechanism of T cell activation may provide new approaches for HIV and immunoactivation therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686495      PMCID: PMC3965330          DOI: 10.4049/jimmunol.1300589

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs.

Authors:  John C Obenauer; Lewis C Cantley; Michael B Yaffe
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

2.  Effect of coinfection with GB virus C on survival among patients with HIV infection.

Authors:  J Xiang; S Wünschmann; D J Diekema; D Klinzman; K D Patrick; S L George; J T Stapleton
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

3.  Infection with GB virus C and reduced mortality among HIV-infected patients.

Authors:  H L Tillmann; H Heiken; A Knapik-Botor; S Heringlake; J Ockenga; J C Wilber; B Goergen; J Detmer; M McMorrow; M Stoll; R E Schmidt; M P Manns
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

4.  Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile.

Authors:  Giuseppe Nunnari; Luciano Nigro; Filippo Palermo; Massimo Attanasio; Annemarie Berger; Hans W Doerr; Roger J Pomerantz; Bruno Cacopardo
Journal:  Ann Intern Med       Date:  2003-07-01       Impact factor: 25.391

5.  Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.

Authors:  Steven G Deeks; Christina M R Kitchen; Lea Liu; Hua Guo; Ron Gascon; Amy B Narváez; Peter Hunt; Jeffrey N Martin; James O Kahn; Jay Levy; Michael S McGrath; Frederick M Hecht
Journal:  Blood       Date:  2004-04-29       Impact factor: 22.113

6.  Persistent immune activation in HIV-1 infection is associated with progression to AIDS.

Authors:  Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

7.  Persistent GB virus C infection and survival in HIV-infected men.

Authors:  Carolyn F Williams; Donna Klinzman; Traci E Yamashita; Jinhua Xiang; Philip M Polgreen; Charles Rinaldo; Chenglong Liu; John Phair; Joseph B Margolick; Dietmar Zdunek; Georg Hess; Jack T Stapleton
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

8.  Association of hepatitis C virus envelope proteins with exosomes.

Authors:  Francesca Masciopinto; Cinzia Giovani; Susanna Campagnoli; Luisa Galli-Stampino; Piero Colombatto; Maurizia Brunetto; T S Benedict Yen; Michael Houghton; Piero Pileri; Sergio Abrignani
Journal:  Eur J Immunol       Date:  2004-10       Impact factor: 5.532

9.  Proline-rich sequences that bind to Src homology 3 domains with individual specificities.

Authors:  K Alexandropoulos; G Cheng; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

10.  Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4.

Authors:  K Saksela; G Cheng; D Baltimore
Journal:  EMBO J       Date:  1995-02-01       Impact factor: 11.598

View more
  25 in total

Review 1.  Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets.

Authors:  Gyongyi Szabo; Fatemeh Momen-Heravi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-06-21       Impact factor: 46.802

Review 2.  Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection.

Authors:  Ernest T Chivero; Jack T Stapleton
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

3.  Flow Virometry to Analyze Antigenic Spectra of Virions and Extracellular Vesicles.

Authors:  Anush Arakelyan; Wendy Fitzgerald; Sonia Zicari; Murad Vagida; Jean-Charles Grivel; Leonid Margolis
Journal:  J Vis Exp       Date:  2017-01-25       Impact factor: 1.355

4.  Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Authors:  Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

Review 5.  Immunoactivation at the crossroads of human disease.

Authors:  Leonid Margolis
Journal:  Am J Med       Date:  2015-01-28       Impact factor: 4.965

Review 6.  A novel T cell evasion mechanism in persistent RNA virus infection.

Authors:  Jack T Stapleton; Jinhua Xiang; James H McLinden; Nirjal Bhattarai; Ernest T Chivero; Donna Klinzman; Thomas M Kaufman; Qing Chang
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

7.  GBV-C infection and risk of NHL among U.S. adults.

Authors:  Cindy M Chang; Jack T Stapleton; Donna Klinzman; James H McLinden; Mark P Purdue; Hormuzd A Katki; Eric A Engels
Journal:  Cancer Res       Date:  2014-08-12       Impact factor: 12.701

8.  Human Hepegivirus-1: Innocent Traveler, Helpful Symbiote, or Insidious Pathogen?

Authors:  Abraham J Kandathil; Ashwin Balagopal
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

9.  Downregulation of Cytokines and Chemokines by GB Virus C After Transmission Via Blood Transfusion in HIV-Positive Blood Recipients.

Authors:  Marion C Lanteri; Farnaz Vahidnia; Sylvia Tan; Jack T Stapleton; Philip J Norris; John Heitman; Xutao Deng; Sheila M Keating; Don Brambilla; Michael P Busch; Brian Custer
Journal:  J Infect Dis       Date:  2014-11-25       Impact factor: 5.226

10.  Antigenic composition of single nano-sized extracellular blood vesicles.

Authors:  Anush Arakelyan; Oxana Ivanova; Elena Vasilieva; Jean-Charles Grivel; Leonid Margolis
Journal:  Nanomedicine       Date:  2014-12-03       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.